Suppr超能文献

治疗前失访的相关因素:监测数据分析。

Factors associated with being lost to follow-up before completing tuberculosis treatment: analysis of surveillance data.

机构信息

London School of Hygiene and Tropical Medicine, London, UK.

出版信息

Epidemiol Infect. 2013 Jun;141(6):1223-31. doi: 10.1017/S095026881200163X. Epub 2012 Jul 30.

Abstract

Completion of treatment is key to tuberculosis control. Using national surveillance data we assessed factors associated with tuberculosis patients being lost to follow-up before completing treatment ('lost'). Patients reported in England, Wales and Northern Ireland between 2001 and 2007 who were lost 12 months after beginning treatment were compared to those who completed, or were still on treatment, using univariable and multivariable logistic regression. Of 41 120 patients, men [adjusted odds ratio (aOR) 1·29; 95% confidence interval (CI) 1·23-1·35], 15- to 44-year-olds (P<0·001), and patients with pulmonary sputum smear-positive disease (aOR 1·25, 95% CI 1·12-1·45) were at higher risk of being lost. Those recently arrived in the UK were also at increased risk, particularly those of the White ethnic group (aOR 6·39, 95% CI 4·46-9·14). Finally, lost patients had a higher risk of drug resistance (aOR 1·41, 95% CI 1·17-1·69). Patients at risk of being lost require enhanced case management and novel case retention methods are needed to prevent this group contributing towards onward transmission.

摘要

完成治疗是结核病控制的关键。我们利用国家监测数据评估了与结核病患者在完成治疗前(“失访”)失访相关的因素。将 2001 年至 2007 年期间在英格兰、威尔士和北爱尔兰报告的治疗开始后 12 个月失访的患者与完成治疗或仍在治疗的患者进行比较,采用单变量和多变量逻辑回归。在 41120 名患者中,男性(调整后的优势比[aOR]1.29;95%置信区间[CI]1.23-1.35)、15-44 岁患者(P<0.001)和肺部痰涂片阳性疾病患者(aOR 1.25,95%CI 1.12-1.45)更有可能失访。最近抵达英国的患者也面临更高的风险,尤其是白人种族群体(aOR 6.39,95%CI 4.46-9.14)。最后,失访患者有更高的耐药风险(aOR 1.41,95%CI 1.17-1.69)。有失访风险的患者需要加强病例管理,需要采用新的病例保留方法来防止这一群体导致疾病继续传播。

相似文献

1
Factors associated with being lost to follow-up before completing tuberculosis treatment: analysis of surveillance data.
Epidemiol Infect. 2013 Jun;141(6):1223-31. doi: 10.1017/S095026881200163X. Epub 2012 Jul 30.
4
[Risk factors associated to tuberculosis patients with positive sputum microscopy].
Gac Sanit. 2001 Nov-Dec;15(6):506-12. doi: 10.1016/s0213-9111(01)71613-5.
6

引用本文的文献

2
Digital technologies and loss to follow-up for TB patients.
Int J Tuberc Lung Dis. 2021 Oct 1;25(10):871-872. doi: 10.5588/ijtld.21.0234.
8
Tuberculosis in tropical areas and immigrants.
Mediterr J Hematol Infect Dis. 2014 Jun 1;6(1):e2014043. doi: 10.4084/MJHID.2014.043. eCollection 2014.

本文引用的文献

2
"It is more than the issue of taking tablets": the interplay between migration policies and TB control in Sweden.
Health Policy. 2010 Sep;97(1):26-31. doi: 10.1016/j.healthpol.2010.02.014. Epub 2010 Mar 29.
3
Increase in extrapulmonary tuberculosis in England and Wales 1999-2006.
Thorax. 2009 Dec;64(12):1090-5. doi: 10.1136/thx.2009.118133. Epub 2009 Oct 22.
4
Monitoring tuberculosis treatment outcome: analysis of national surveillance data from a clinical perspective.
Thorax. 2008 May;63(5):440-6. doi: 10.1136/thx.2006.073916. Epub 2007 Jul 5.
5
Tuberculosis treatment outcome monitoring in England, Wales and Northern Ireland for cases reported in 2001.
J Epidemiol Community Health. 2007 Apr;61(4):302-7. doi: 10.1136/jech.2005.044404.
6
Tuberculosis in London: the importance of homelessness, problem drug use and prison.
Thorax. 2007 Aug;62(8):667-71. doi: 10.1136/thx.2006.065409. Epub 2007 Feb 8.
7
Tuberculosis treatment outcomes in Europe: a systematic review.
Eur Respir J. 2005 Sep;26(3):503-10. doi: 10.1183/09031936.05.00103504.
8
Deciphering an outbreak of drug-resistant Mycobacterium tuberculosis.
J Clin Microbiol. 2003 Jan;41(1):67-72. doi: 10.1128/JCM.41.1.67-72.2003.
9
Revised international definitions in tuberculosis control.
Int J Tuberc Lung Dis. 2001 Mar;5(3):213-5.
10
Tuberculosis drug resistance in England and Wales. How much is 'home-grown'?
Epidemiol Infect. 2000 Oct;125(2):463-4. doi: 10.1017/s0950268899004434.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验